CAMBRIDGE, Mass--17 Jan--PRNewswire-AsiaNet/InfoQuest
Mersana, a cancer therapeutics company, announced today that John H. van Duzer, Ph.D. has joined the company as Vice President of Manufacturing & Pharmaceutical Sciences.
"John van Duzer adds a critical component to the Mersana management team with his manufacturing and development experience," said Julie A. Olson, Ph.D., President and CEO at Mersana. "As a clinical development-stage company, manufacturing plays a key role in the advancement of our products and John's contributions will impact our entire pipeline. We are also fortunate that
Dr. van Duzer has over eighteen years of experience in pharmaceutical R&D. As a Vice President of Manufacturing at ActivBiotics, he led efforts for the development of a liquid dosage form of a rifamycin, an oral antibacterial agent. Prior to joining ActivBiotics, Dr. van Duzer served as the Director of Chemistry at Inotek Corporation, a clinical-stage, drug development company.
About Mersana Therapeutics, Inc.
Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert polymer hat can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer-camptothecin conjugate which is currently in Phase 1 clinical trials, and
Fleximer(R) is a trademark of Mersana Therapeutics, Inc.
SOURCE: Mersana Therapeutics, Inc.
CONTACT: Pete Leone,
Chief Operating Officer of Mersana Therapeutics, Inc.,
+1-617-498-0020;
or Media, Kathryn Morris of KMorrisPR for Mersana Therapeutics, Inc.,
+1-845-635-9828,
--Distributed by AsiaNet ( www.asianetnews.net )--
Mersana, a cancer therapeutics company, announced today that Timothy B. Lowinger, Ph.D., has joined the company as Chief Scientific Officer. "We are thrilled that Tim is now a part of the Mersana team," said Julie A. Olson, President and CEO at Mersana. "His extensive leadership in oncology research and his experience with polymer-based drug systems are an ideal match for Mersana. In addition to the important impact he will have on our newest programs, his contributions toward advancing our lead